On August 18, 2025, Evolent Health, Inc. announced plans to offer $140 million in convertible senior notes due 2031, expecting to use $100 million of the proceeds to repurchase existing notes and $40 million for Class A common stock buybacks. Additionally, they are under investigation by the DOJ regarding a former customer's allegations related to unsupported Medicare diagnosis codes, covering since January 1, 2016.